Becton, Dickinson and Company $BDX Position Reduced by Trust Co. of Vermont

Trust Co. of Vermont reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 18.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,622 shares of the medical instruments supplier’s stock after selling 8,574 shares during the period. Trust Co. of Vermont’s holdings in Becton, Dickinson and Company were worth $7,495,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Focus Financial Network Inc. lifted its position in shares of Becton, Dickinson and Company by 2.2% during the third quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier’s stock worth $504,000 after purchasing an additional 58 shares during the last quarter. Phillips Wealth Planners LLC increased its holdings in Becton, Dickinson and Company by 2.7% in the third quarter. Phillips Wealth Planners LLC now owns 2,241 shares of the medical instruments supplier’s stock valued at $430,000 after buying an additional 58 shares during the last quarter. Union Bancaire Privee UBP SA increased its holdings in Becton, Dickinson and Company by 25.7% in the fourth quarter. Union Bancaire Privee UBP SA now owns 289 shares of the medical instruments supplier’s stock valued at $56,000 after buying an additional 59 shares during the last quarter. Legacy Solutions LLC raised its stake in Becton, Dickinson and Company by 5.3% during the fourth quarter. Legacy Solutions LLC now owns 1,172 shares of the medical instruments supplier’s stock valued at $227,000 after buying an additional 59 shares in the last quarter. Finally, CX Institutional lifted its holdings in Becton, Dickinson and Company by 3.6% during the 3rd quarter. CX Institutional now owns 1,731 shares of the medical instruments supplier’s stock worth $324,000 after buying an additional 60 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This trade represents a 11.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the sale, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 2,713 shares of company stock worth $536,881. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.4%

Shares of Becton, Dickinson and Company stock opened at $156.61 on Thursday. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. The business’s 50 day simple moving average is $177.66 and its 200-day simple moving average is $186.92. The stock has a market capitalization of $44.59 billion, a price-to-earnings ratio of 25.55, a PEG ratio of 11.40 and a beta of 0.29. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The business had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The business’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company declared that its Board of Directors has initiated a share repurchase program on Tuesday, January 27th that allows the company to repurchase $10.00 million in shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th were given a dividend of $1.05 per share. The ex-dividend date was Tuesday, March 10th. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Analyst Ratings Changes

Several brokerages have recently commented on BDX. JPMorgan Chase & Co. decreased their target price on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Jefferies Financial Group reduced their price objective on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. Royal Bank Of Canada set a $172.00 price objective on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Citigroup lowered their target price on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. Finally, Barclays began coverage on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. They set an “overweight” rating and a $202.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average price target of $191.62.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.